Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06293898 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06293898 · ClinicalTrials.gov record · last posted 2026-07-20

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Name: Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors — clinical trial record (NCT06293898)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorSystImmune Inc.

Started2024-02-09

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2024-03-01; most recent amendment 2026-07-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details

NCT Number	NCT06293898
Lead Sponsor	SystImmune Inc.
Conditions	Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer +2 more
Enrollment	280 participants
Start Date	2024-02-09
Primary Completion	2028-12-15 (estimated)
Study Completion	2029-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-20